Picton Mahoney Asset Management Acquires 7,734 Shares of Boston Scientific Corporation $BSX

Picton Mahoney Asset Management boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 2.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 340,103 shares of the medical equipment provider’s stock after buying an additional 7,734 shares during the quarter. Picton Mahoney Asset Management’s holdings in Boston Scientific were worth $33,205,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Level Four Advisory Services LLC raised its position in shares of Boston Scientific by 8.4% in the 3rd quarter. Level Four Advisory Services LLC now owns 10,030 shares of the medical equipment provider’s stock worth $979,000 after acquiring an additional 781 shares in the last quarter. CI Investments Inc. raised its holdings in Boston Scientific by 8.7% in the third quarter. CI Investments Inc. now owns 1,615,574 shares of the medical equipment provider’s stock worth $157,728,000 after purchasing an additional 128,875 shares in the last quarter. Segall Bryant & Hamill LLC lifted its position in shares of Boston Scientific by 155.9% during the third quarter. Segall Bryant & Hamill LLC now owns 240,780 shares of the medical equipment provider’s stock valued at $23,507,000 after buying an additional 146,683 shares during the last quarter. Monetary Management Group Inc. boosted its holdings in shares of Boston Scientific by 42.4% in the 3rd quarter. Monetary Management Group Inc. now owns 3,360 shares of the medical equipment provider’s stock valued at $328,000 after buying an additional 1,000 shares in the last quarter. Finally, Becker Capital Management Inc. boosted its holdings in shares of Boston Scientific by 20.2% in the 3rd quarter. Becker Capital Management Inc. now owns 3,512 shares of the medical equipment provider’s stock valued at $343,000 after buying an additional 591 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on BSX. Robert W. Baird reduced their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Evercore decreased their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. National Bank Financial set a $115.00 price objective on Boston Scientific in a research report on Monday, February 2nd. Mizuho reduced their target price on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Finally, Weiss Ratings downgraded Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $108.36.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $73.69 on Wednesday. The business has a fifty day moving average of $86.46 and a 200 day moving average of $95.15. Boston Scientific Corporation has a 1 year low of $72.69 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a market capitalization of $109.35 billion, a price-to-earnings ratio of 37.98, a price-to-earnings-growth ratio of 1.05 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the company earned $0.70 earnings per share. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.